Nath Bio-Genes (India) Ltd. (NATHBIOGEN) AI Stock Analysis

• Market Cap: ₹2.87B
• Dividend Yield: 1.26%
• Average Volume (3M): 2.58K
• Price to Earnings (P/E): 6.6
• Beta (1Y): 1.22
• Revenue Growth: 18.68%
• EPS Growth: 16.47%
• Country: IN
• Employees: 423
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Agricultural Inputs
• EPS (TTM): 2.54
• Shares Outstanding: 19,004,000
• 10 Day Avg. Volume: 2,256
• 30 Day Avg. Volume: 2,581
• PEG Ratio: -3.00
• Price to Book (P/B): 0.47
• Price to Sales (P/S): 0.82
• P/FCF Ratio: 31.02
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: ₹161.00 ▲(1.39% Upside)

The overall stock score is influenced by strong financial performance and attractive valuation, offset by bearish technical indicators. The company's solid profitability and financial stability are key strengths, but the current negative market momentum poses a risk.

Positive Factors

Revenue Growth

Strong revenue growth reflects successful product adoption and market expansion, supporting long-term business sustainability.

Profitability

Consistent profitability indicates effective cost management and pricing strategies, enhancing financial resilience and shareholder value.

Cash Generation

Improved cash generation supports operational flexibility and investment in growth opportunities, strengthening long-term financial health.

Negative Factors

Cash Flow Variability

Variability in cash flow can impact liquidity management, potentially constraining the company's ability to invest in growth and manage obligations.

Debt Management

Moderate reliance on debt requires careful management to avoid financial strain, especially in volatile market conditions.

Operating Efficiency

Fluctuating margins may indicate challenges in maintaining consistent operational efficiency, impacting profitability and competitive positioning.

Nath Bio-Genes (India) Ltd. Business Overview & Revenue Model

Company Description

Nath Bio-Genes (India) Limited engages in the production, processing, and marketing of hybrid and GM seeds in India and internationally. It operates in two segments, Agricultural Activities and Trading Activities. The company offers seeds for cereals, such as maize, paddy, millet, wheat, and jowar; fruit seeds; fiber and oil seeds, including cotton and mustard; and seeds for vegetables comprising chilli, okra, tomato, brinjal, bottle gourd, bitter gourd, sponge gourd, ridge gourd, cucumber, coriander, onion, sweet peeper, green paeas, pumpkin, tinda, cabbage, and French beans. It also provides crop protection supplements, such as WINPro GOLii, WINall, and Win Chi Win growth enhancer; and forage supplements, including NUTRIMAX GOLD and NUTRIMAX for enhanced fodder yields. The company offers its products through a network of distributors, dealers, and processing plants. Nath Bio-Genes (India) Limited was founded in 1979 and is based in Aurangabad, India.

How the Company Makes Money

Nath Bio-Genes generates revenue primarily through the sale of hybrid seeds and related agricultural products. Its revenue model is anchored in the development and commercialization of high-yield and pest-resistant seed varieties, which are sold to farmers across India and potentially in international markets. Key revenue streams include sales from hybrid seeds, as well as associated products such as fertilizers and crop protection chemicals which complement their seed offerings. The company also benefits from partnerships with agricultural research institutions and collaborations with other agribusiness companies, enhancing its R&D capabilities and expanding its market reach. Seasonal demand for seeds, driven by planting cycles and agricultural trends, significantly influences the company's earnings, alongside potential government policies supporting agricultural innovation.

Nath Bio-Genes (India) Ltd. Financial Statement Overview

Summary

Nath Bio-Genes demonstrates strong profitability and financial stability with positive growth trends. The company effectively manages its equity and debt levels but should monitor cash flow variability for sustained liquidity.

Income Statement

The company shows a solid performance in terms of profitability with a healthy gross profit margin and stable net profit margin. Revenue growth from 2024 to 2025 was significant, indicating a positive trajectory. However, EBIT and EBITDA margins have shown slight fluctuations over the years, suggesting some variability in operating efficiency.

Balance Sheet

Nath Bio-Genes maintains a strong equity base with a relatively low debt-to-equity ratio, indicating financial stability. The return on equity has improved, reflecting effective use of shareholder funds. However, the equity ratio indicates a moderate reliance on debt, which could pose risks if not managed carefully.

Cash Flow

The cash flow statement reflects a positive trend in free cash flow growth, indicating improved cash generation from operations. The operating cash flow to net income ratio suggests efficient conversion of income into cash. However, the free cash flow to net income ratio has shown variability, which may affect liquidity.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.05B	3.65B	2.48B	3.01B	2.78B	3.07B
Gross Profit	2.13B	2.29B	1.03B	1.67B	1.54B	1.71B
EBITDA	577.27M	497.98M	536.39M	488.91M	-497.06M	684.33M
Net Income	425.26M	386.00M	396.19M	350.11M	-673.38M	556.62M
Balance Sheet
Total Assets	0.00	10.26B	8.80B	7.93B	7.42B	7.90B
Cash, Cash Equivalents and Short-Term Investments	888.99M	888.99M	774.10M	379.90M	41.68M	292.11M
Total Debt	0.00	1.23B	1.10B	1.05B	929.59M	965.67M
Total Liabilities	-6.44B	3.82B	2.70B	2.20B	2.00B	1.76B
Stockholders Equity	6.44B	6.44B	6.10B	5.73B	5.42B	6.13B
Cash Flow
Free Cash Flow	0.00	96.61M	478.18M	358.18M	-39.70M	-104.86M
Operating Cash Flow	0.00	175.81M	745.94M	383.67M	170.46M	11.13M
Investing Cash Flow	0.00	-39.62M	-274.01M	-28.84M	-198.66M	-102.82M
Financing Cash Flow	0.00	-21.30M	-77.78M	-16.68M	-222.27M	164.01M

Nath Bio-Genes (India) Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 158.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NATHBIOGEN, the sentiment is Negative. The current price of 158.8 is above the 20-day moving average (MA) of 154.98, above the 50-day MA of 157.56, and below the 200-day MA of 172.75, indicating a bearish trend. The MACD of -0.99 indicates Positive momentum. The RSI at 39.11 is Neutral, neither overbought nor oversold. The STOCH value of 11.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NATHBIOGEN.

Nath Bio-Genes (India) Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATHBIOGEN	63 Neutral	₹2.87B	6.59	―	1.26%	18.68%	16.47%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
ARIES	62 Neutral	₹4.06B	10.71	―	0.38%	13.83%	33.88%
HARRMALAYA	58 Neutral	₹3.02B	10.33	―	―	4.81%	―
NOVAAGRI	58 Neutral	₹3.52B	12.43	―	―	13.15%	-20.51%

Nath Bio-Genes (India) Ltd. Corporate Events

Nath Bio-Genes Shuts Trading Window Ahead of Q3 FY26 Results

Nath Bio-Genes (India) Ltd. has announced that its trading window for dealing in the company’s securities will be closed from 1 January 2026 until 48 hours after the announcement of its unaudited financial results for the quarter and nine months ended 31 December 2025, in line with SEBI’s Prohibition of Insider Trading Regulations and its internal code of conduct. The company will separately notify the date of the board meeting for approving these unaudited results, a procedural move aimed at preventing insider trading and ensuring fair disclosure practices for investors and other market participants.

Nath Bio-Genes Ensures Regulatory Compliance with SEBI Regulations

Nath Bio-Genes (India) Ltd. has submitted a compliance certificate for the quarter ending September 30, 2025, in accordance with SEBI (Depositories and Participants) Regulations, 2018. This submission, confirmed by their Registrar and Share Transfer Agent, Bigshare Services Pvt. Ltd., ensures that all securities received for dematerialization have been processed and listed appropriately, maintaining regulatory compliance and transparency for stakeholders.